Accès ouvert
2023
article
OpenAlex
Mark Edwards, Gordon Forbes, Neil Walker, Dion Morton et autres
INTRODUCTION: Postoperative morbidity and mortality in patients undergoing major emergency gastrointestinal surgery are a major burden on healthcare systems. Optimal management of perioperative intravenous fluids may reduce mortality rates and improve outcomes from surgery. Previous small trials of cardiac-output guided haemodynamic therapy …
gb
(code pays fourni par la source)
2009
conference-abstract
OpenAlex
Peter J.H. Jones, Anne C. Goldberg, Howard R. Knapp, Matt Kelly et autres
2009
conference-abstract
OpenAlex
Michael H. Davidson, Robert Guthrie, Michael P. Kelly, Carolyn M. Setze et autres
2009
article
OpenAlex
Syed Mohiuddin, Matt Kelly, Carolyn M. Setze, Jean-Claude Ansquer et autres
us, fr
(code pays fourni par la source)
2007
conference-abstract
OpenAlex
James B. Nelson, Joseph L. Chin, William T. Love, C. Schulman et autres
5018 Introduction: Atrasentan is a potent oral, selective endothelin A receptor antagonist with biological activity in patients with HRPC. This randomized phase III trial of atrasentan vs placebo was conducted in 941 men with nonmetastatic HRPC whose prostate-specific antigen (PSA) was rising …
us, ca
(code pays fourni par la source)
2006
conference-abstract
OpenAlex
Daniel P. Petrylak, Supriya G. Mohile, Gary Shelton, Robert Carr et autres
14512 Background: ATN (Xinlay) is an oral selective endothelin A receptor antagonist in Phase III clinical development for the treatment of HRPC. ATN is extensively metabolized by oxidation and glucuronidation. In vitro, CYP3A is the predominant isozyme involved in oxidative metabolism of …
us
(code pays fourni par la source)
Accès ouvert
2006
conference-abstract
OpenAlex
Eric Wu, P.M. Mulani, M.J. Farrell, D. Sleep
2005
conference-abstract
OpenAlex
Daniel J. George, Jon P. Gockerman, William P. Petros, S. Haley et autres
4667 Background: Docetaxel is first-line treatment for men with metastatic HRPC. New combinations with targeted therapies may improve clinical responses to this regimen. Atrasentan is an endothelin receptor A (ETA) inhibitor with an IC50 in the pM range. Clinical studies suggest atrasentan …
us
(code pays fourni par la source)
2004
conference-abstract
OpenAlex
James B. Nelson, Ann Allen, S. M. Hulting, Jeffrey D. Isaacson et autres
4554 Background: Prostate-specific antigen doubling time (PSADT) has been identified as a predictor of outcome in prostate cancer. Atrasentan, a potent, selective, oral endothelin A receptor antagonist, significantly decreased time to prostate-specific antigen (PSA) progression in a randomized, double-blind, placebo-controlled phase 2 …
us
(code pays fourni par la source)
2004
conference-abstract
OpenAlex
Susan Yount, David Cella, Parvez Mulani, D. Sleep et autres
4582
us
(code pays fourni par la source)
2004
conference-abstract
OpenAlex
Susan Yount, David Cella, Parvez Mulani, D. Sleep et autres
4582 Background: For men with advanced cancer facing reduced life expectancy and no possibility of cure, symptom relief and maintenance of function are primary objectives of treatment. The Functional Assessment of Cancer Therapy-Prostate (FACT-P) quality of life (QOL) instrument incorporates a disease-specific, …
us
(code pays fourni par la source)
2004
conference-abstract
OpenAlex
Jeremy B. Nelson, Ann Allen, S. M. Hulting, Jeffrey D. Isaacson et autres
4554 Background: Prostate-specific antigen doubling time (PSADT) has been identified as a predictor of outcome in prostate cancer. Atrasentan, a potent, selective, oral endothelin A receptor antagonist, significantly decreased time to prostate-specific antigen (PSA) progression in a randomized, double-blind, placebo-controlled phase 2 …
us
(code pays fourni par la source)